



# IV2-113E

English

# Invitron Glargine ELISA Kit

For Research Use Only



Invitron Ltd.
Wyastone Business Park, Wyastone Leys
Monmouth NP25 3SR, UK
www.invitron.com

R.08 2017/02 © Invitron Ltd.

Manufactured for Immuno-Biological Laboratories Inc. (IBL-America)
8201 Central Avenue, NE, Suite P
Minneapolis, MN 55432
Tel: 1-888-523-1246
info@ibl-america.com
ibl-america.com

### **Definitions**



Instructions for use



Catalogue number



Use by

LOT

Lot/Batch Code



Storage temperature limitations



Manufactured by



Contains sufficient for <N> tests



# Invitron Glargine ELISA Kit

# Intended Use

The Invitron Glargine kit is an immunometric assay for the quantitative measurement of insulin glargine in human samples. Measurements of glargine are useful in monitoring diabetic patients treated with glargine.

### Summary and Explanation

The long acting insulin analogue, insulin glargine is widely used in the treatment of patients with both type 1 and type 2 diabetes. Insulin glargine differs from human insulin by the presence of two additional arginine residues at the C-terminus of the B chain and the substitution of asparagine with glycine at the C-terminus of the A Chain. As a consequence of these small changes, most assays for human insulin do not detect the analogue or measure it with variable cross-reactivity. The Invitron Glargine Kit has been developed as a specific quantitative test for insulin glargine in human plasma samples.

### Principle

The Invitron Glargine ELISA is a two-site immunoassay, employing a monoclonal antibody immobilised on microtitre wells and a soluble antibody labelled with horseradish peroxidase (HRP). A plasma sample is incubated in the microtitre well together and, after a wash step, the antibody-HRP conjugate solution is added. A second incubation is followed by a further wash step to remove unbound antibody-HRP conjugate before measurement. A substrate for the enzyme is added to each well and after a short incubation a further reagent is added to terminate the reaction. The intensity of the colour developed in each well is quantified in a microtitre plate reader set to record transmitted light at a wavelength of 450 nm.

### Materials Provided

#### Coated Microtitre Plate

(12 x 8 wells) stripwells coated with a specific monoclonal antibody. The plate is sealed inside a foil pouch with a desiccant to maintain a moisture-free environment.

#### Sample Buffer

(12 ml) Ready to use. Protein matrix including preservatives.

#### HRP Conjugate Concentrate

HRP enzyme labelled antibody (1.0ml).

#### Conjugate Diluent

(1 x 11.0ml) Ready to use for diluting the antibody-HRP concentrate to its working strength. Protein matrix including preservatives.

#### Standards

(5 x 1.0ml lyophilized) of 5 concentrations – (typically) 0, 10, 40, 100, 200 mU/l – glargine in a serum matrix, lyophilized and sealed under vacuum for stability. Refer to the kit certificate of analysis for actual concentrations.

#### Controls

(2 x 1ml lyophilized) samples containing low (A) and high (B) concentrations of glargine in a buffer matrix. *Each laboratory should establish its own expected concentration range.* 

#### Substrate Solution

Tetramethylbenzidine (TMB) substrate. Supplied ready to use.

#### Stop Solution

ELISA stop reagent. Supplied ready to use.

#### Wash Buffer Concentrate.

Phosphate buffer including detergent (30x concentrate).

#### Product Insert

# Materials Required But Not Provided

- Deionised water
- Uncoated strips
- Sealers to cover microtitre plate
- Calibrated Precision Micropipettes with disposable tips.
- Vortex-Mixer
- Standard laboratory glass or plastic vials, cups, etc.
- Automatic Microplate Washer.
- Microtitre plate reader at 450 nm (background subtraction at 620/650).

### Warnings and Precautions

- For *in-vitro* diagnostic use only. For professional use only.
- For information on hazardous substances included in the kit please refer to the Material Safety Data Sheet.
- Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled.
- Wear disposable latex gloves and appropriate protective clothing when handling specimens and reagents. Microbial contamination of reagents or specimens may give false results.
- Handling should be in accordance with the procedures defined by an appropriate national biohazard safety guideline or regulation.
- Do not use reagents beyond expiry date as shown on the kit labels.
- Optimal test results are only obtained when using calibrated pipettes.
- Do not mix or use components from kits with different lot numbers.
- This kit contains no human-derived material.

### Specimen Collection & Storage

Use only EDTA Plasma. Do not use severely haemolysed specimens.

#### Specimen Collection

**Plasma:** Whole blood should be collected into a tube containing EDTA anticoagulant and centrifuged immediately after collection. Plasma should be frozen at -20°C as soon as possible after separation.

#### Specimen Storage

Specimens should be stored frozen at -20°C prior to assay. Thawed samples should be inverted several times prior to testing.

# Preparation, Storage & Stability of Reagents

When stored at 2-8°C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date. Opened reagents must be stored at 2-8°C. Microtitre wells must be stored at 2-8°C. Once the foil bag has been opened, care should be taken to close it tightly again. Opened kits retain activity for two months if stored as described above.

#### Standards and Controls

Reconstitute each of the standards and controls by the addition of 1.0 ml of deionised water. Allow these to stand for 5 minutes, then mix gently to ensure all solids are dissolved. Reconstituted standards and controls may be stored for 48 hours at 4°C. For longer periods standards and controls must be stored frozen at -20°C. Do not freeze/thaw more than once.

### **HRP Conjugate**

Transfer the entire contents of the vial containing HRP Conjugate Concentrate (1.0ml) into the bottle of Conjugate Diluent (11.0ml) and mix thoroughly. Use working strength HRP Conjugate within 24 hours.

#### Wash Buffer

Make up working strength Wash Buffer by diluting 1 part of Wash Buffer concentrate with 29 parts of deionised water. Chill working strength Wash Buffer to 2-8°C prior to use (for example refrigerate overnight). Working strength wash buffer can be stored for up to 2 weeks at 2-8°C.

### Assay Procedure


- Bring all kit components and samples to room temperature before use.
- Assemble the required number of coated strips in the plate holder.
   Any strips not used immediately may be stored inside a sealed polythene bag with silica gel desiccant. Make sure to fill remaining spaces in the plate holder with uncoated strips to ensure uniform heat transfer during incubation.
- 3. Pipette 100 µl Sample Buffer into each well.
- 4. Pipette **25 µl Standard or Sample** into the respective wells. It is recommended that all standards and samples are run in duplicate.
- 5. Attach a plate sealer and incubate for **2 hours at Room Temperature** (18-22 °C).
- Remove the plate sealer and perform 3 wash cycles with chilled\* working strength Wash Buffer (300 μl each cycle) using an automatic plate washer.
- 7. Pipette 100 µl working strength antibody conjugate into each well.
- 8. Attach a plate sealer and incubate for a further **4 hr at 4°C** (2-8 °C).
- Remove the plate sealer and perform 3 wash cycles with chilled\* working strength Wash Buffer using an automatic plate washer.
- 10. Add **100 μl Substrate Solution** to each well. Incubate for 15 minutes at room temperature (18-22 °C) in the dark.
- 11. Add **100 μl Stop Solution** to each well.
- Measure light transmission in a microtitre plate reader set to 450 nm and, if available, with a background subtraction measured at an OD of 620/650 nm.

N.B. It is important to use an automatic plate washer for this assay. Manual washing may lead to poor precision of replicates and/or drift effect caused by inconsistent timing.

<sup>\*</sup> Using wash buffer chilled to 2-8°C is not essential but will ensure optimum sensitivity. Immediately before washing the microplate plate, ensure that the reagent lines in the washer have been fully primed with cold wash buffer.

# Typical Standard Curve

This curve is for illustration only and must not be used for result calculation.



OD 450/620
0.015
0.040
0.250
1.100
2.300

# Calculation of Results

The results may be calculated automatically using curve fitting software (e.g. 4-parameter or cubic spline). Different data reduction functions may give slightly different results. The concentration of the samples can be read directly from this standard curve. Samples with concentrations higher than that of the highest standard should be further diluted. For the calculation of the concentrations this dilution factor must be taken into account.

### **Expected Values**

It is strongly recommended that each laboratory determines its own normal and abnormal values.

# Assay Performance

#### Sensitivity

Sensitivity was estimated as two standard deviations from the mean of duplicates of a zero standard in 3 separate assays.

Sensitivity: 0.8 mU/l at 95% confidence limits

#### Recovery

Five EDTA plasma samples were spiked with glargine at 3 levels. Recoveries are shown as percentages of the expected result.

Glargine Spike (mU/I)	Sample recovery (%)				
	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5
15	118.1	119.0	103.1	95.6	107.7
70	111.0	110.4	105.7	102.6	94.0
140	106.6	103.5	94.0	103.5	92.8

Mean spiking recovery was 104.5%.

### Linearity

Three EDTA plasma patient samples containing glargine were diluted 1:2 in Sample Buffer. The following table shows the measured glargine concentrations of the undiluted and diluted specimens.

Dilution	Measured glargine (mU/l)			
	Sample 1	Sample 2	Sample 3	
0	149.3	144.9	131.6	
1:2	71.0	69.8	72.3	

N.B. Sample Buffer should not be used for dilutions greater than 1:2. If necessary, it is recommended that large sample dilutions are made in EDTA plasma.

### **High Dose Hook Effect**

Because of the assay architecture, which employs separate incubations with solid phase and labelled antibodies, no high dose hook effect is experienced.

### **Cross Reactivity**

Cross reactivity with Insulin and other insulin analogues was determined by measuring each substance in the glargine assay at a concentration of 250 mU/l. Results are expressed as percentages of the reactivity of an identical concentration of glargine.

Peptide	CR (%)
Glargine	100
Human Insulin	7.5
Detemir	0
Lispro	0
Glulisine	0
Aspart	0

### Limitations

- For Research Use Only.
- Only if test instructions are rigidly followed will optimum results be achieved.
- Use fresh plasma or specimens frozen and thawed no more than twice.
   Specimens that are improperly stored or are subjected to multiple freeze-thaw cycles may yield spurious results.
- Reproducible results depend on careful pipetting, observation of incubation periods and temperature, as well as thorough mixing of all prepared solutions.
- While washing, check that all wells are filled evenly with Wash Buffer, and that there is no residue in the wells.

### For additional information and product support please contact:

IBL-America 8201 Central Avenue, NE, Suite P Minneapolis, MN 55432

Tel: 1-888-523-1246 info@ibl-america.com ibl-america.com